Sprycel® (dasatinib) – Expanded orphan indication
November 10, 2017 – Bristol-Myers Squibb announced the FDA approval of Sprycel (dasatinib) tablets, for the treatment of pediatric patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase.
Download PDF
